Selene Therapeutics

Company Overview

Snapshot

Founded in September 2020 by Inna Slutsky and Neta Pessah, Selene Therapeutics operates with 1–10 employees. The company has secured funding across two rounds from three investors. In June 2024, the company received a grant from the Israel Innovation Authority.

Business overview

Selene Therapeutics is a Health Tech & Life Sciences company focused on developing a new therapeutic strategy for treating refractory epilepsy. The company's core technology involves developing small molecules as inhibitors of dihydroorotate dehydrogenase, a mitochondrial enzyme crucial for cellular homeostatic processes. Selene Therapeutics operates in the Pharmaceuticals sector, specifically within Drugs Discovery & Development, targeting the Life Sciences and Pharmaceutical markets with a B2B business model.

Company Intelligence Q&A

What is Selene Therapeutics' primary focus?

Selene Therapeutics is developing a new therapeutic strategy for treating refractory epilepsy by regulating the neuronal activity set point through reducing the neuronal mean firing rate.

What is the company's core technology?

Selene Therapeutics aims to develop small molecules for inhibitors of dihydroorotate dehydrogenase, a mitochondrial enzyme located on the inner mitochondrial membrane that participates in several key cellular homeostatic processes.

When was Selene Therapeutics founded?

Selene Therapeutics was founded in September 2020.

Who are the founders of Selene Therapeutics?

The founders of Selene Therapeutics are Inna Slutsky and Neta Pessah.

What was a recent significant event for Selene Therapeutics?

In June 2024, Selene Therapeutics secured a grant from the Israel Innovation Authority.